CSBio CSBio

X
[{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Announces FDA Approval Of Updated Label For Seysara\u00ae (Sarecycline) Tablets","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Announces FDA Approval Of Klisyri\u00ae (Tirbanibulin), A New Innovative Topical Treatment for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall U.S. Launches Klisyri\u00ae (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Receives Positive CHMP Opinion for Klisyri\u00ae\u25bc (Tirbanibulin), An Innovative Topical Treatment for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Receives European Commission approval of Klisyri\u00ae\u25bc (tirbanibulin) for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Phased European Launch of Klisyri\u00ae (tirbanibulin) for the Treatment of Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and Almirall Enter an Exclusive Licensing Agreement to Market Finjuve in the Middle East and North Africa Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall's Klisyri\u00ae (tirbanibulin) Receives Strong Recommendation in American Academy of Dermatology AK Guideline Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall PROSES Study Demonstrates Appropriate Acne Treatment Decreases The Burden Of Impact On Acne Sufferers\u2019 Social And Emotional Wellbeing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Almirall"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Ilumetri (tildrakizumab) is a humanized mAb that targets the p19 subunit of IL-23 and inhibits the release of proinflammatory cytokines and chemokines with limited impact on the rest of the immune system. It is indicated for adults with moderate-to-severe plaque psoriasis.

            Lead Product(s): Tildrakizumab

            Therapeutic Area: Dermatology Product Name: Ilumetri

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SEYSARA (sarecycline) tablet is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

            Lead Product(s): Sarecycline

            Therapeutic Area: Dermatology Product Name: Seysara

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KLISYRI (tirbanibulin) met key clinical criteria required for its inclusion with 49% of KLISYRI patients achieving complete clearance (100%) of lesions (9% for vehicle) and no patients withdrew from clinical trials due to adverse events.

            Lead Product(s): Tirbanibulin

            Therapeutic Area: Dermatology Product Name: Klisyri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product Finjuve, in certain MENA markets and Almirall will be responsible for product supply.

            Lead Product(s): Finasteride

            Therapeutic Area: Dermatology Product Name: Finjuve

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Klisyri® (tirbanibulin) is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that we believe represents a significant step forward in the treatment of actinic keratosis (AK) of the face and scalp in adults.

            Lead Product(s): Tirbanibulin

            Therapeutic Area: Dermatology Product Name: Klisyri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Athenex

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Klisyri® (tirbanibulin) is a topical microtubule inhibitor indicated for the treatment of actinic keratosis (AK) of the face or scalp in adults and it acts through a selective antiproliferative mechanism of action.

            Lead Product(s): Tirbanibulin

            Therapeutic Area: Dermatology Product Name: Klisyri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In the KX01-AK-004 study, complete clearance was observed in 54% of the patients treated with tirbanibulin versus 13% for vehicle-treated groups.

            Lead Product(s): Tirbanibulin

            Therapeutic Area: Dermatology Product Name: Klisyri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Klisyri® is a novel, topical, first-in-class microtubule inhibitor that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), and proven efficacy and safety profile.

            Lead Product(s): Tirbanibulin

            Therapeutic Area: Dermatology Product Name: Klisyri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp.

            Lead Product(s): Tirbanibulin

            Therapeutic Area: Dermatology Product Name: Klisyri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Athenex

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline. This information is included in the Microbiology Section (12.4) of the prescribing information.

            Lead Product(s): Sarecycline

            Therapeutic Area: Dermatology Product Name: Seysara

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY